Health Care • Medicinal Chemicals and Botanical Products
$61.52 ▲ +0.45
(+0.74%)
MKT CAP: $131.93B • VOL: 4.82M
52W L $52 52W H $67
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$52
MEDIAN
$69
MEAN
$70
HIGH
$84
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BTI TAPE
BTI // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $74.44 | $70.75 | 2025-02-14 | $55.98 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $77.52 | $72.59 | 2025-02-06 | $57.83 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $70.13 | $67.67 | 2025-01-29 | $59.06 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $62.75 | — | 2025-01-17 | $60.29 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $54.14 | $58.44 | 2025-01-09 | $54.75 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $73.21 | $63.98 | 2024-12-18 | $53.52 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $59.67 | $62.14 | 2024-12-04 | $57.21 | -4.3% | 48% | C |